North Dallas Bank & Trust Co. Invests $970,000 in Stryker Corporation $SYK

North Dallas Bank & Trust Co. bought a new position in shares of Stryker Corporation (NYSE:SYK) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 2,451 shares of the medical technology company’s stock, valued at approximately $970,000.

Other hedge funds have also recently bought and sold shares of the company. Coppell Advisory Solutions LLC raised its position in shares of Stryker by 5.4% during the second quarter. Coppell Advisory Solutions LLC now owns 1,473 shares of the medical technology company’s stock valued at $580,000 after buying an additional 76 shares during the last quarter. B. Riley Wealth Advisors Inc. bought a new position in Stryker during the second quarter valued at about $6,262,000. Newbridge Financial Services Group Inc. lifted its position in shares of Stryker by 26.2% in the 2nd quarter. Newbridge Financial Services Group Inc. now owns 183 shares of the medical technology company’s stock worth $72,000 after acquiring an additional 38 shares during the period. Advisory Services Network LLC lifted its position in shares of Stryker by 23.5% in the 2nd quarter. Advisory Services Network LLC now owns 24,621 shares of the medical technology company’s stock worth $9,669,000 after acquiring an additional 4,685 shares during the period. Finally, Delos Wealth Advisors LLC bought a new stake in shares of Stryker during the second quarter valued at approximately $47,000. 77.09% of the stock is owned by institutional investors.

Insider Transactions at Stryker

In other news, Director Ronda E. Stryker sold 276,173 shares of the firm’s stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $353.28, for a total value of $97,566,397.44. Following the completion of the sale, the director directly owned 2,702,108 shares in the company, valued at approximately $954,600,714.24. This trade represents a 9.27% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CAO William E. Berry, Jr. sold 1,953 shares of the company’s stock in a transaction dated Friday, November 14th. The stock was sold at an average price of $365.49, for a total transaction of $713,801.97. Following the transaction, the chief accounting officer owned 2,833 shares in the company, valued at approximately $1,035,433.17. This trade represents a 40.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 522,118 shares of company stock worth $185,381,932. Insiders own 5.90% of the company’s stock.

Stryker Trading Up 0.3%

Shares of SYK stock opened at $353.99 on Friday. The company has a market capitalization of $135.37 billion, a P/E ratio of 46.52, a P/E/G ratio of 2.51 and a beta of 0.89. Stryker Corporation has a 12-month low of $329.16 and a 12-month high of $406.19. The company has a quick ratio of 1.13, a current ratio of 1.85 and a debt-to-equity ratio of 0.68. The firm has a 50-day moving average price of $366.81 and a 200 day moving average price of $378.46.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, October 30th. The medical technology company reported $3.19 earnings per share for the quarter, topping the consensus estimate of $3.13 by $0.06. Stryker had a net margin of 12.07% and a return on equity of 24.07%. The company had revenue of $6.06 billion during the quarter, compared to analyst estimates of $6.04 billion. During the same quarter last year, the business posted $2.87 earnings per share. The company’s revenue was up 10.2% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. Research analysts forecast that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 30th. Shareholders of record on Wednesday, December 31st will be paid a $0.88 dividend. This is an increase from Stryker’s previous quarterly dividend of $0.84. This represents a $3.52 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date of this dividend is Wednesday, December 31st. Stryker’s payout ratio is presently 44.15%.

Analysts Set New Price Targets

Several research analysts recently commented on SYK shares. Barclays raised their target price on Stryker from $443.00 to $453.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 22nd. Wall Street Zen downgraded shares of Stryker from a “buy” rating to a “hold” rating in a report on Saturday. Sanford C. Bernstein reissued an “outperform” rating on shares of Stryker in a research note on Monday, November 3rd. Evercore ISI dropped their price target on shares of Stryker from $410.00 to $405.00 and set an “outperform” rating for the company in a research report on Friday, October 31st. Finally, UBS Group set a $408.00 price objective on Stryker in a report on Monday, October 13th. Twelve investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $431.83.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.